Pyrazinamide — CAS 98-96-4

Pyrazinamide is a critical first-line antitubercular drug used in the treatment of active tuberculosis. Mediocon Inc manufactures this high-purity API at its GMP-certified facility in Aurangabad, Maharashtra, India. It is a prodrug that is converted by Mycobacterium tuberculosis to the active form pyrazinoic acid, which disrupts bacterial membrane energy metabolism.

• First-line treatment of active pulmonary tuberculosis
• Combination therapy in the intensive phase of TB treatment (DOTS)
• Treatment of drug-susceptible and some drug-resistant TB strains
• Preventive therapy in latent TB infection protocols

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support